Brett Chevalier

Brett Chevalier currently serves as the Chief Scientific Officer at Anterra Capital since September 2018 and holds multiple roles including Scientific Co-Founder and Interim VP of Operations at Orogen Therapeutics, and Board Observer positions at BiomEdit and Animol Discovery, Inc. Previously, Brett was the Head of Operations at CAMP4 Therapeutics and advised Corvium after founding and serving as Chief Scientific Officer there. Brett also worked as a New Venture Associate at Flagship Ventures and as a Research Scientist at the Whitehead Institute. Brett's early career involved establishing a core laboratory as a Senior Scientist at Agilent Technologies. Educational credentials include a Merck LSRF Fellowship at MIT focusing on stem and iPS cells and a PhD in Protein Design and Engineering from the University of Washington, along with a BA in Biology from Carleton College.